20676 ⎘
Medicinal preparations containing materials or reaction products thereof with undetermined constitution; Microorganisms or materials therefrom; Viruses; Subviral particles; Bacteriophages Oncolytic viruses not provided for in groups -
USE OF DR-18 AND ONCOLYTIC VACCINIA VIRUS IN PREPARATION OF ANTI-TUMOR DRUG
#2IRF MODULATOR-EXPRESSING ONCOLYTIC VIRUSES FOR TREATING CANCER
#3M1 VIRUS MUTANT AND USE THEREOF
#4PHOTOSENSITIVE HYBRID VESICLES AND THE FABRICATION METHODS AND APPLICATIONS THEREOF
#5NOVEL USE OF ONCOLYTIC VIRUS
#6RECOMBINANT VIRUS EXPRESSING INTERLEUKIN-12
#7SYNTHETIC ONCOLYTIC LNP-REPLICON RNA AND USES FOR CANCER IMMUNOTHERAPY
#8COMBINATION THERAPY OF ONCOLYTIC VIRUS DRUGS FOR CANCER TREATMENT
#9CHIMERIC POXVIRUSES
#10METHODS AND COMPOSITIONS COMPRISING TUMOR SUPPRESSOR GENE THERAPY AND CD122/CD132 AGONISTS FOR THE TREATMENT OF CANCER
#11FUSION PROTEIN COMPRISING A SURFACTANT-PROTEIN-D AND A MEMBER OF THE TNFSF
#12METHODS OF TREATING BLADDER CANCER
#13ONCOLYTIC VIRUS SIMULTANEOUSLY EXPRESSING CD55 AND CD59
#14ENHANCING ONCOLYTIC VIROTHERAPY WITH A COMBINATION OF NUCLEAR EXPORT INHIBITOR AND MYXOMA VIRUS ACTIVATING CELL DEATH PATHWAYS
#15ONCOLYTIC VIRUS EXPRESSING A CAR T CELL TARGET AND USES THEREOF
#16PHAGE COMPOSITIONS FOR ESCHERICHIA COMPRISING CRISPR-CAS SYSTEMS AND METHODS OF USE THEREOF
#17ONCOLYTIC VIRUS THERAPY
#18CANCER THERAPY
#19GENETICALLY MODIFIED ENTEROVIRUS VECTORS WITH ENHANCED GENOMIC STABILITY
#20THERAPEUTIC AGENT COMPRISING MULTISPECIFIC ANTIBODY AND USE THEREOF IN TUMOR THERAPY
#21COMPOSITIONS OF CD47/SIRP-ALPHA IMMUNE CHECKPOINT INHIBITORS AND USES THEREOF
#22BISPECIFIC T-CELL ENGAGER, RECOMBINANT ONCOLYTIC VIRUS THEREOF, AND USE THEREOF
#23METHODS FOR CASCADE AMPLIFICATIONS OF THERAPEUTIC PAYLOADS (CATP) & COMPOSITIONS FOR CANCER IMMUNOTHERAPIES AND GENE THERAPY
#24PRODUCTION OF RNA POLYNUCLEOTIDES ENCODING PICORNAVIRUS
#25CANCER THERAPIES COMPRISING A NUCLEAR EXPORT INHIBITOR AND AN ONCOLYTIC VIRUS
#26NEOADJUVANT CANCER TREATMENT
#27COMPOUND FOR INCREASING EFFICACY OF ONCOLYTIC VIRUSES
#28MUTANT ORF VIRUSES AND USES THEREOF
#29RECOMBINANT MVA OR MVADELE3L EXPRESSING HUMAN FLT3L AND USE THEREOF AS IMMUNO-THERAPEUTIC AGENTS AGAINST SOLID TUMORS
#30ONCOLYTIC VIRUSES AND METHODS OF USE
#31RECOMBINANT ONCOLYTIC VIRUS AND USE THEREOF
#32COMBINATIONS OF CHECKPOINT INHIBITORS AND ONCOLYTIC VIRUS FOR TREATING CANCER
#33NEWCASTLE DISEASE VIRUSES AND USES THEREOF
#34METHOD FOR PRODUCING AN ANTITUMORAL ARENAVIRUS AS WELL AS ARENAVIRUS MUTANTS
#35ONCOLYTIC VIROTHERAPY COMPOSITIONS AND METHODS
#36FOAMY VIRUSES AND METHODS OF USE
#37BACTERIOPHAGE HAVING BACTERIOLYSIS ACTIVITY ON XANTHOMONAS SPP.
#38METHODS AND COMPOSITIONS FOR USING ACTIVATED LYMPHOCYTES IN THE TREATMENT OF DISEASE
#39IMMUNOMODULATORY FUSION PROTEINS
#40TNFSF-L Fusion Proteins and Uses Thereof
#41INTERLEUKIN-18 VARIANTS AND METHODS OF USE
#42Oncolytic Immunotherapy by Tumor Micro-Environment Remodeling
#43ADENOVIRUS ARMED WITH BISPECIFIC T CELL ACTIVATOR
#44VLP IMMUNOTHERAPY COMBINED WITH ABLATION
#45Oncolytic Immunotherapy by Tumor Micro-Environment Remodeling
#46ONCOLYTIC VIRUS REGIMENS FOR THE TREATMENT OF CANCER
#47Combination Treatment
#48COMPOSITIONS AND METHODS OF SENECA VALLEY VIRUS (SVV) RELATED CANCER THERAPY
#49NKp46-Targeted Modified IL-2 Polypeptides and Uses Thereof
#50NOVEL COMBINATIONS OF ANTIBODIES AND USES THEREOF
#51COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF
#52ALTERED VIRUS
#53E PROTEIN-MUTATED WEST NILE VIRUS USED AS LIVEATTENUATED VACCINE AND ONCOLYTIC DRUG FOR CANCER THERAPY
#54INTERLEUKIN-18 VARIANTS AND METHODS OF USE
#55Cancer Treatments
#56COMPOSITION AND METHODS INCLUDING RECOMBINANT VIRUSES MODULATING ARGININE BIOSYNTHESIS
#57ARMED SENECA VALLEY VIRUS ONCOLYTIC THERAPY COMPOSITIONS AND METHODS THEREOF
#58COMPOSITIONS AND METHODS OF USE FOR HUMAN RHINOVIRUSES
#59USE OF A BIRNAVIRUS ALONE OR IN COMBINATION THERAPY FOR THE TREATMENT OF CANCER
#603-SUBSTITUTED PIPERIDINE COMPOUNDS FOR CBL-B INHIBITION, AND USE THEREOF
#61PHARMACEUTICAL COMPOSITIONS COMPRISING VANADIUM SALTS
#62ONCOLYTIC VIRUSES FOR MODIFIED MHC EXPRESSION
#63ONCOLYTIC VIRUSES FOR MODIFIED MHC EXPRESSION
#64RECOMBINANT NEWCASTLE DISEASE VIRUS AND PREPARATION METHOD THEREFOR, RECOMBINANT PLASMID, AND USE THEREOF
#65ARENAVIRUSES FOR USE IN THE TREATMENT AND/OR PREVENTION OF TUMORS AND METHOD FOR PRODUCING ARENAVIRUSES WITH (IM-PROVED) TUMOR-REGRESSION PROPERTIES
#66MIR-375- AND MIR-1-REGULATED COXSACKIEVIRUS B3 HAS NO PANCREAS AND HEART TOXICITY BUT STRONG ANTITUMOR EFFICIENCY IN COLORECTAL CARCINOMAS
#67CANCER TREATMENTS
#68GROUP B ADENOVIRUS ENCODING AN ANTI-TCR-COMPLEX ANTIBODY OR FRAGMENT
#69ONCOLYTIC VIRUS BASED CANCER THERAPY
#70PHARMACEUTICAL KIT AND USES THEREOF
#71MODIFIED ORTHOPOXVIRUS VECTORS
#72ONCOLYTIC VIRUS COMBINED WITH CAR T CELLS FOR ANTI-TUMOR THERAPY
#73CHIMERIC ANTIGEN RECEPTOR TARGETING ONCOLYTIC VIRUS-DERIVED PROTEIN, IMMUNOCYTE EXPRESSING SAME, AND USES OF BOTH
#74METHODS FOR DETERMINING TUMOR IMMUNE STATUS
#75COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF
#76MATERIALS AND METHODS FOR TREATING CANCER
#77Pharmaceutical Composition of a Recombinant Adeno-Associated Virus Vector and its Application
#78SENECA VALLEY VIRUS (SVV) CELLULAR RECEPTOR TARGETED ONCOTHERAPY
#79MODIFIED ORTHOPOXVIRUS VECTORS
#80ONCOLYTIC VIRUS COMBINED WITH CAR T CELLS FOR ANTI-TUMOR THERAPY
#81RECOMBINANT NEWCASTLE DISEASE VIRUS RNDV-VEGF-TRAP, GENOME THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF
#82ENCAPSULATED RNA POLYNUCLEOTIDES AND METHODS OF USE
#83Oncolytic virus improved in safety and anticancer effect
#84SENECA VALLEY VIRUS COMBINATION THERAPY TO TREAT A CANCER REFRACTORY TO A CHECKPOINT INHIBITOR
#85ONCOLYTIC VIRUSES THAT EXPRESS MULTI-SPECIFIC IMMUNE CELL ENGAGERS
#86COMPOSITIONS AND METHODS OF TREATMENT OF TUMORS EXPRESSING PUTATIVE ZIKA VIRUS RECEPTOR PROTEINS
#87ONCOLYTIC VIRUS COMPRISING IMMUNOMODULATORY TRANSGENES AND USES THEREOF
#88METHODS AND MATERIALS FOR TREATING CANCER
#89CANCER THERAPY INVOLVING CAR-ENGINEERED T-CELLS AND PARVOVIRUS H-1
#90ONCOLYTIC VIRUS AND USES THEREOF
#91ANTI-CANCER-ASSOCIATED NON-TUMOR CELL AGENT COMPRISING VIRUS
#92IMMUNOTHERAPEUTIC VACCINE AND ANTIBODY COMBINATION THERAPY
#93SYNTHETIC ONCOLYTIC LNP-REPLICON RNA AND USES FOR CANCER IMMUNOTHERAPY
#94Oncolytic viruses targeting STAT3
#95ONCOLYTIC VIRUSES ENCODING RECOMBINANT TRANSFORMING GROWTH FACTOR (TGF)-BETA MONOMERS AND USES THEREOF
#96Oncolytic viruses for sensitizing tumor cells to killing by natural killer cells
#97AN IMMUNE CHECKPOINT-MODULATING VSV-NDV HYBRID VIRUS FOR ONCOLYTIC VIRUS IMMUNOTHERAPY OF CANCER
#98HSV VECTORS WITH ENHANCED REPLICATION IN CANCER CELLS
#99RECOMBINANT VIRUSES, SURFACE-ENGINEERED DELIVERY SYSTEMS AND RELATED METHODS
#100ONCOLYTIC VACCINIA VIRUS DEFICIENT IN LARGE REGION OF GENES
#101INTERLEUKIN-18 VARIANTS AND METHODS OF USE
#102NOVEL RECOMBINANT VACCINIA VIRUS AND USE THEREOF
#103Upregulation of Cathelicidin Gene Expression as an Adjuvant to Other Treatments for Diseases
#104Immuno-modulated replication-efficient Vaccinia virus strain
#105MUTANT ORF VIRUSES AND USES THEREOF
#106Oncolytic viruses for modified MHC expression
#107INTERLEUKIN-18 VARIANTS AND METHODS OF USE
#108MEDICAMENT FOR TREATING CANCER, IMMUNOSTIMULANT, AND METHOD FOR SCREENING FOR ANTI-CANCER SUBSTANCE
#109Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy
#110Oncolytic Vaccinia Virus
#111ONCOLYTIC VIRUSES AS ADJUVANTS
#112TREATMENT OF CANCER HARBORING MUTATIONS IN THE TP53 GENE AND/OR POST-TRANSLATIONAL MODIFICATIONS IN THE P53 PROTEIN WITH PARVOVIRUSES
#113PHARMACEUTICAL COMPOSITION OF ENZYMES AND VIRUSES AND APPLICATION THEREOF
#114ISOLATED RECOMBINANT ONCOLYTIC POXVIRUS CAPABLE OF BEING REGULATED AND CONTROLLED BY MICRORNA AND USE THEREOF
#115Oncolytic viruses for modified MHC expression
#116Oncolytic Immunotherapy by Tumor Micro-Environment Remodeling
#117INTERLEUKIN-18 VARIANTS AND METHODS OF USE
#118METHODS FOR COMBINING ADOPTIVE T CELL THERAPY WITH ONCOLYTIC VIRUS ADJUNCT THERAPY
#119RAPID VACCINE PLATFORM
#120RECOMBINANT VACCINIA VIRUS
#121DELIVERY OF SIALIDASE TO CANCER CELLS, IMMUNE CELLS AND THE TUMOR MICROENVIRONMENT
#122PHARMACEUTICAL FORMULATION COMPRISING A COMBINATION OF RECOMBINANT NEWCASTLE DISEASE VIRUSES FOR THE TREATMENT OF CANCER
#123CD80 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF
#124N6-Methyladenosine Regulators in Uterine Fibroids
#125Oncolytic virus for colorectal cancer treatment using colorectal cancer cell-specific infectious newcastle disease virus and composition for colorectal cancer treatment using same
#126RECOMBINANT MYXOMA VIRUSES AND USES THEREOF
#127COMBINATION ANTI-CANCER THERAPIES WITH INDUCERS OF IRON-DEPENDENT CELLULAR DISASSEMBLY
#128ANTITUMOR VIRUS
#129Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors
#130IMMUNOTHERAPEUTIC TREATMENT OF CANCER
#131METHODS AND COMPOSITIONS FOR KILLING A TARGET BACTERIUM
#132Method For Determining Responsiveness To Prostate Cancer Treatment
#133KIT FOR PREPARING NANOPARTICLE COMPOSITION FOR DRUG DELIVERY
#134Immuno-Oncolytic Therapies
#135CLONAL STRAINS OF ATTENUATED VACCINIA VIRUSES AND METHODS OF USE THEREOF
#136VARIANT ONCOLYTIC VACCINIA VIRUS AND METHODS OF USE THEREOF
#137TUMOR-TARGETING PROTEIN OR FRAGMENT THEREOF, ANTIBODY BINDING THERETO AND USE THEREOF
#138METHODS AND COMPOSITIONS FOR KILLING A TARGET BACTERIUM
#139ONCOLYTIC VIROTHERAPY AND IMMUNOTHERAPY
#140TREATMENT FOR PRIMARY AND METASTATIC CANCER
#141MODIFIED ORTHOPOXVIRUS VECTORS
#142METHODS AND COMPOSITIONS FOR KILLING A TARGET BACTERIUM
#1433-substituted piperidine compounds for Cbl-b inhibition, and use thereof
#144DELIVERY OF SIALIDASE TO CANCER CELLS, IMMUNE CELLS AND THE TUMOR MICROENVIRONMENT
#145IRF MODULATOR-EXPRESSING ONCOLYTIC VIRUSES FOR TREATING CANCER
#146PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING ANTICANCER VIRUS, IMMUNE CHECKPOINT INHIBITOR AND HYDROXYUREA AS ACTIVE INGREDIENTS
#147LMP-1 EXPRESSING CELLS AND METHODS OF USE THEREOF
#148PROCESS OF MAKING MEMBRANE LIPID COATED NANOPARTICLES
#149RECOMBINANT VACCINIA VIRUS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
#150Oncolytic poliovirus for human tumors
#151NEW ONCOLYTIC NEWCASTLE DISEASE VIRUSES AND RECOMBINANT NDV STRAINS
#152Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy
#153THERAPEUTIC AGENTS COMPRISING ONCOLYTIC VACCINIA VIRUSES AND NK CELLS, AND USES THEREOF FOR DRUGS FOR TREATMENT OF TUMORS AND/OR CANCERS
#154ANTI-CANCER ONCOLYTIC VIRUS COMBINATION THERAPIES AND ELITE RESPONDER SELECTION PLATFORMS
#155Methods of treating bladder cancer
#156RECOMBINANT ONCOLYTIC NEWCASTLE DISEASE VIRUSES WITH INCREASED ACTIVITY
#157M1 VIRUS MUTANT AND USE THEREOF
#158VACCINIA VIRUS THAT INDUCES CELL FUSION AND USE THEREOF
#159TARGETED CANCER THERAPY
#160METHODS FOR INDUCING AN IMMUNE RESPONSE AGAINST NEOANTIGENS
#161PHARMACEUTICAL COMPOSITION COMPRISING VACCINIA VIRUS AND HYDROXYUREA AS ACTIVE INGREDIENT FOR TREATMENT OF CANCER
#162METHODS AND COMPOSITIONS FOR IMPROVING ONCOLYTIC VIRUS INFECTION FOR NONPERMISSIVE CANCERS
#163METHODS OF TREATING BLADDER CANCER
#164PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING VACCINIA VIRUS AND GRANULOPOIESIS INHIBITOR AS ACTIVE INGREDIENTS
#165Striatin interacting protein inhibitor and use thereof in preparation of anti-tumor drug
#166ONCOLYTIC VACCINIA VIRUS
#167NEW VIRUS PARTICLES FOR THERAPEUTIC PURPOSES
#168GENETICALLY MODIFIED ENTEROVIRUS VECTORS
#169Novel oncolytic parvoviruses with enhanced cargo capacity, stable shRNA expression cassette and novel immunogenic properties
#170ENGINEERED VACCINIA VIRUS
#171POLYMER NANOPARTICLE COMPOSITION FOR DELIVERING VIRUS, AND PREPARATION METHOD THEREFOR
#172SECOND GENERATION SENECA VALLEY VIRUS ONCOLYTIC THERAPY: COMPOSITIONS AND METHODS THEREOF
#173COMBINATION IMMUNOTHERAPY APPROACH FOR TREATMENT OF CANCER
#174ATTENUATED YELLOW FEVER VIRUS AND USES THEREOF FOR THE TREATMENT OF CANCER
#175APMV AND USES THEREOF FOR THE TREATMENT OF CANCER
#176ONCOLYTIC VIROTHERAPY AND IMMUNOTHERAPY
#177IL-36 CYTOKINE EXPRESSING ONCOLYTIC VIRUSES FOR TREATING CANCER
#178USE OF MVA OR MVADELTAE3L AS IMMUNOTHERAPEUTIC AGENTS AGAINST SOLID TUMORS
#179ONCOLYTIC VIRUS WITH IMPROVED SAFETY AND ANTICANCER EFFECTS
#180COMPOSITIONS AND METHODS OF USING SENECA VALLEY VIRUS (SVV) FOR TREATING CANCER
#181METHODS OF INDUCING AN IMMUNE RESPONSE
#182Enveloped Virus Resistant to Complement Inactivation for the Treatment of Cancer
#183CD80 variant immunomodulatory proteins and uses thereof
#184METHODS FOR INDUCING AN IMMUNE RESPONSE AGAINST NEOANTIGENS
#185CD80 variant immunomodulatory proteins and uses thereof
#186SEQUENTIAL HETEROLOGOUS BOOST ONCOLYTIC VIRAL IMMUNOTHERAPY
#187ONCOLYTIC VIRUSES AND METHODS FOR USING ONCOLYTIC VIRUSES
#188ONCOLYTIC VIRUSES TARGETING STAT3
#189ONCOLYTIC VIRUSES TARGETING STAT3
#190A MODIFIED ONCOLYTIC VIRUS, COMPOSITION AND USE THEREOF
#191Platform Oncolytic Vector for Systemic Delivery
#192ENCAPSULATED RNA POLYNUCLEOTIDES AND METHODS OF USE
#193Engineered immunostimulatory bacterial strains and uses thereof
#194ONCOLYTIC ADENOVIRUS COMPOSITIONS
#195OPTIMIZED ONCOLYTIC VIRUSES AND USES THEREOF
#196OPTIMIZED ONCOLYTIC VIRUSES AND USES THEREOF
#197ONCOLYTIC MYXOMA VIRUS EXPRESSING FAST P14 TO TREAT HEMATOLOGICAL CANCER
#198Platform oncolytic vector for systemic delivery
#199Seneca valley virus (SVV) cellular receptor targeted oncotherapy
#200Modified Extracellular Enveloped Virus
#201RECOMBINANT VACCINIA VIRUS
#202Method for producing an antitumoral arenavirus as well as arenavirus mutants
#203Platform oncolytic vector for systemic delivery
#204ENCAPSULATED POLYNUCLEOTIDES AND METHODS OF USE
#205ANTI-CANCER-ASSOCIATED NON-TUMOR CELL AGENT COMPRISING VIRUS
#206Therapeutic agents comprising nucleic acids and TCR modified immune cells and uses thereof
#207MUTANT VACCINIA VIRUSES AND USE THEREOF
#208Bacteriophage for treatment and prevention of and infections
#209CANCER IMMUNOTHERAPY USING VIRUS PARTICLES AND IMMUNE CHECKPOINT THERAPY
#210ENHANCED CANCER TREATMENT AND MONITORING USING RECOMBINANT VECTORS
#211CD80 variant immunomodulatory proteins and uses thereof
#212HIGH MOBILITY GROUP BOX I MUTANT
#213ONCOLYTIC VACCINIA VIRUS CANCER THERAPY
#214ZIKA VIRUS TREATMENT OF CD24-POSITIVE TUMORS AND DISEASES ASSOCIATED WITH ABNORMAL T CELL ACTIVATION AND TREATING OR PREVENTING ZIKA VIRUS INFECTIONS
#215Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy
#216Transluminal Delivery of Viruses for Treatment of Diseased Tissue
#217Materials and methods for treatment with oncolytic viruses and modified CAR T cells
#218Methods of treating cancer with TNF expressing myxoma virus
#219MSC- AND EXOSOME-BASED IMMUNOTHERAPY
#220ONCOLYTIC VIRUS PLATFORM TO TREAT HEMATOLOGICAL CANCER
#221RNA viruses for immunovirotherapy
#222SYNTHETIC CHIMERIC VACCINIA VIRUS
#223Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor
#224USE OF PROTEASOME INHIBITOR AND ALPHAVIRUS IN PREPARATION OF ANTI-TUMOR MEDICAMENT
#225ECHO-7 ONCOLYTIC VIRUS FOR USE IN THE TREARMENT OF UVEAL MELANOMA
#226RECOMBINANT MYXOMA VIRUSES AND USES THEREOF
#227PLATFORM ONCOLYTIC VECTOR FOR SYSTEMIC DELIVERY
#228PURIFIED COMPOSITIONS OF ENTEROVIRUSES AND METHODS OF PURIFICATION WITH GLUTATHIONE AFFINITY CHROMATOGRAPHY
#229ONCOLYTIC RHABDOVIRUS
#230COMBINED USE OF SQUIRREL POXVIRUS AND MYXOMA POXVIRUS, FOR TREATING CANCER
#231INCREASED ACTIVITY OF ONCOLYTIC NEWCASTLE DISEASE VIRUS
#232Use of Oncolytic Herpes Simplex Virus, Alone or in Combination with Immune Check-Point Inhibitor, in the Treatment of Cancer
#233Zika virus strains for treatment of glioma
#234Oncolytic viruses for sensitizing tumor cells to killing by natural killer cells
#235Immunomodulatory fusion proteins
#236TREATING CANCER WITH VIRAL NUCLEIC ACID
#237NEOADJUVANT CANCER TREATMENT
#238HERPES SIMPLEX VIRUS (HSV) ANTICANCER THERAPIES
#239EGFR BINDING MOIETY-PRESENTING BACTERIOPHAGES FOR TUMOUR TREATMENT
#240METHODS AND COMPOSITIONS COMPRISING TUMOR SUPPRESSOR GENE THERAPY AND CD122/CD132 AGONISTS FOR THE TREATMENT OF CANCER
#241Platform oncolytic vector for systemic delivery
#242IMMUNO-ONCOLYTIC MODIFIED VACCINIA TIAN TAN VIRUS AND METHODS OF TREATING CANCER
#243Methods of treating bladder cancer with an oncolytic virus
#244Methods of Neoplasm Treatment Utilizing Complementary Oncolytic Viruses and CAR T-Cells
#245Oncolytic virus improved in safety and anticancer effect
#246CANCER THERAPY WITH A PARVOVIRUS COMBINED WITH BEVACIZUMAB
#247NEURAL STEM CELL COMPOSITIONS INCLUDING CHIMERIC POXVIRUSES FOR CANCER TREATMENT
#248Foamy viruses and methods of use
#249Swelling-Suppressive Oncolytic Virus
#250Engineered vaccinia virus
#251Oncolytic T7 bacteriophage having cytokine gene and displaying homing peptide on capsid and its use for treating melanoma
#252Oncolytic poliovirus for human tumors
#253PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING ANTICANCER VIRUS AND HYDROXYUREA AS EFFECTIVE COMPONENTS
#254USE OF MEVALONATE METABOLIC PATHWAY INHIBITOR AND ALPHAVIRUS IN PREPARING ANTI-TUMOR DRUG
#255ONCOLYTIC VIRUSES AS ADJUVANTS
#256TROPISM MODIFIED CANCER TERMINATOR VIRUS (AD.5/3 CTV;AD.5/3-CTV-M7)
#257Modified orthopoxvirus vectors
#258COMBINATION OF ONCOLYTIC VIRUS WITH IMMUNE CHECKPOINT MODULATORS
#259Immuno-modulated replication-efficient vaccinia virus strain
#260Combination Treatment
#261COMPOSITIONS AND METHODS FOR PRODUCING DENDRITIC CELLS
#262Methods for combining adoptive T cell therapy with oncolytic virus adjunct therapy
#263DELIVERY OF ONCOLYTIC VIRUSES USING DENDRITIC CELLS
#264VIRAL VECTORS AND THEIR USE IN THERAPEUTIC METHODS
#265NOVEL GENETICALLY ENGINEERED VACCINIA VIRUSES
#266ONCOLYTIC CANCER IMMUNOTHERAPIES AND METHODS OF USE
#267Expression of metabolic modulators in tumor microenvironment to improve tumor therapy
#268Echovirus for treatment of tumors
#2693-substituted piperidine compounds for Cbl-b inhibition, and use thereof
#270Recombinant MVA or MVAΔE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors
#271COMBINATION METHOD FOR TREATMENT OF CANCER
#272APMV AND USES THEREOF FOR THE TREATMENT OF CANCER
#273Genetically engineered vaccinia viruses
#274Isolated Recombinant Oncolytic Poxvirus, Pharmaceutical Composition, and Use Thereof in Treatment of Tumors and/or Cancer
#275Therapeutic compositions and applications that comprise nucleic acids and adoptively transferred immune cell
#276Synthetic oncolytic LNP-replicon RNA and uses for cancer immunotherapy
#277Recombinant vaccinia virus and methods of use thereof
#278TREATMENT OF TRIPLE NEGATIVE BREAST CANCER OR COLORECTAL CANCER WITH LIVER METASTASES WITH AN ANTI PD-L1 ANTIBODY AND AN ONCOLYTIC VIRUS
#279Virus for treatment of tumor
#280Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human FLT3L or GM-CSF for cancer immunotherapy
#281Seneca Valley Virus (SVV) cellular receptor targeted oncotherapy
#282Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors
#283VACCINIA VIRUS FOR GENE-DIRECTED ENZYME PRODRUG THERAPY
#284Parvovirus formulation for treating tumors
#285COMBINATION OF IMMUNO-ONCOLYTIC VIRUS DRUGS FOR ENHANCING SYSTEMIC IMMUNE RESPONSE AND APPLICATION THEREOF
#286ONCOLYTIC VIRUS EXPRESSING A CAR T CELL TARGET AND USES THEREOF
#287Oncolytic virus for expression of immune checkpoint modulators
#288Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia
#289Oncolytic viral delivery of therapeutic polypeptides
#290Method of Selecting Viruses for the Treatment of Cancer
#291COMPOSITION FOR TREATING CANCEROUS CELLS AND A METHOD THEREFOR
#292Use of alphavirus in preparation of antitumor drugs
#293ONCOLYTIC VACCINIA VIRUS AND CHECKPOINT INHIBITOR COMBINATION THERAPY
#294TREATMENT OF CANCER BY INFUSION OF ONCOLYTIC HERPES SIMPLEX VIRUS TO THE BLOOD
#295Multiple transgene recombinant adenovirus
#296Engineered immunostimulatory bacterial strains and uses thereof
#297Newcastle disease viruses and uses thereof
#298P53-targeting vaccines and pd-1 pathway inhibitors and methods of use thereof
#299RECOMBINANT ONCOLYTIC VIRUSES FOR CANCER THERAPY
#300Oncolytic virus growth method and antitumor agent